BioLine Rx (BioLine Rx) EPS (Diluted) : $-0.90 (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx EPS (Diluted)?

BioLine Rx's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

BioLine Rx's EPS (Basic) for the three months ended in Dec. 2023 was $-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

BioLine Rx's EPS without NRI for the three months ended in Dec. 2023 was $-0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.90.

During the past 3 years, the average EPS without NRIGrowth Rate was 25.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 33.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 25.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, BioLine Rx's highest 3-Year average EPS without NRI Growth Rate was 45.20% per year. The lowest was 8.90% per year. And the median was 26.25% per year.

BioLine Rx EPS (Diluted) Historical Data

The historical data trend for BioLine Rx's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx EPS (Diluted) Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-2.55

-1.80

-0.60

-0.45

-0.90

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-	-0.15	-0.30	-0.30	-0.15

Competitive Comparison of BioLine Rx's EPS (Diluted)

For the Biotechnology subindustry, BioLine Rx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's PE Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's PE Ratio falls into.

BioLine Rx EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

BioLine Rx's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-60.614	-	0)	/	64.224
	=	-0.94

BioLine Rx's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-13.884	-	0)	/	71.895
	=	-0.19

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.90

BioLine Rx (NAS:BLRX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioLine Rx EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of BioLine Rx's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.